Inivata today announced it has launched its InVisionFirst Lung liquid biopsy in the U.S. through a commercial partnership with NeoGenomics.
The device is a ctDNA next-generation sequencing liquid biopsy assay testing 37 genes that are relevant to the care of advanced non-small-cell lung cancer. The results are delivered within seven days and the test is covered by Medicare and other private insurance payers.
“Today is a significant step in the commercialization of InVisionFirst-Lung. NeoGenomics has proven capabilities in this field and, since signing our agreement in May this year, I have been hugely impressed by their commitment to bring this important technology to clinicians and patients in the US. Our teams have been working closely together to prepare for this launch and I look forward to our continued collaboration,” Inivata CEO Clive Morris said in a news release.
NeoGenomics has an extensive direct national sales team that serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks and managed care organizations within the U.S.
“Liquid biopsy testing is an increasingly important tool for cancer patients. The launch of InVisionFirst-Lung as part of this suite of liquid biopsy assays exemplifies our commitment to providing the most innovative tests for our clients as soon as they become clinically relevant,” NeoGenomics chief medical officer Lawrence Weiss said.
